Acadia Pharmaceuticals Inc (ACAD) 20.77 $ACAD
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
Business Wire - Tue Aug 05, 3:01PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2014.
Financial Results, Clinical Trial Initiations, Drug Designations, Appointments, and Study Results - Research Reports on Cubist, Jazz, InterMune, NPS Pharmaceuticals and ACADIA
PR Newswire - Wed Jul 30, 8:00AM CDT
Today, Analysts Review released its research reports regarding Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), InterMune, Inc. (NASDAQ: ITMN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5256-100free.
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
Business Wire - Tue Jul 29, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2014 on Tuesday, August 5, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Tuesday, August 5, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
Alzheimer's Needs Cures, Not Pyrrhic Victories
Cheryl Swanson, The Motley Fool - Motley Fool - Sun Jul 20, 2:00PM CDT
It's a tough call for investors. With the clinical trial failure rate for Alzheimer's drugs an astounding 99.6%, major drugmakers have seen one promising Alzheimer's treatment after another fail. The list include Bapineuzumab ( Pfizer / Johnson...
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
Business Wire - Tue Jul 15, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective today. Mr. Davis will report to Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer.
Critical Alerts For Zillow, ACADIA Pharmaceuticals, Potbelly, American Tower, and HollyFrontier Released By InvestorsObserver
PR Newswire - Wed Jul 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for Z, ACAD, PBPB, AMT, and HFC.
Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma
Are Investors Wrong About Acadia Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 3:49PM CDT
Short interest is a key metric to pay attention to because it may signal that a stock could be ready to fall -- or continue a recent downturn. Acadia Pharmaceuticals has been one of the top performing biopharmas even since its experimental...
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
Business Wire - Tue Jun 17, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014, at 1:30 p.m. Eastern Time in New York City.
Critical Alerts For JPMorgan, Darden Restaurants, BorgWarner, Acadia, and AFLAC Released By InvestorsObserver
PR Newswire - Fri May 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JPM, DRI, BWA, ACAD, and AFL.
10.5% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu May 29, 5:05PM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 10.47% as of today's recent price of $21.25.
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
Business Wire - Tue May 27, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 10:00 a.m. Eastern Time in New York City.
Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 17.3% (ACAD)
Comtex SmarTrend(R) - Thu May 22, 11:05AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 17.34% as of today's recent price of $19.62.
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
Business Wire - Tue Apr 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City.
aTyr Pharma Appoints David M. Weiner, M.D., as Chief Medical Officer
PR Newswire - Fri Mar 28, 7:00AM CDT
aTyr Pharma ("aTyr"
, a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders.
Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
Acadia Pharmaceuticals Has Returned 14.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Tue Mar 11, 9:14AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.28% as of today's recent price of $28.44.
Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
Business Wire - Tue Aug 05, 3:01PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2014.
Financial Results, Clinical Trial Initiations, Drug Designations, Appointments, and Study Results - Research Reports on Cubist, Jazz, InterMune, NPS Pharmaceuticals and ACADIA
PR Newswire - Wed Jul 30, 8:00AM CDT
Today, Analysts Review released its research reports regarding Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), InterMune, Inc. (NASDAQ: ITMN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5256-100free.
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
Business Wire - Tue Jul 29, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2014 on Tuesday, August 5, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Tuesday, August 5, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
Alzheimer's Needs Cures, Not Pyrrhic Victories
Cheryl Swanson, The Motley Fool - Motley Fool - Sun Jul 20, 2:00PM CDT
It's a tough call for investors. With the clinical trial failure rate for Alzheimer's drugs an astounding 99.6%, major drugmakers have seen one promising Alzheimer's treatment after another fail. The list include Bapineuzumab ( Pfizer / Johnson...
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
Business Wire - Tue Jul 15, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective today. Mr. Davis will report to Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer.
Critical Alerts For Zillow, ACADIA Pharmaceuticals, Potbelly, American Tower, and HollyFrontier Released By InvestorsObserver
PR Newswire - Wed Jul 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for Z, ACAD, PBPB, AMT, and HFC.
Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma
Are Investors Wrong About Acadia Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 3:49PM CDT
Short interest is a key metric to pay attention to because it may signal that a stock could be ready to fall -- or continue a recent downturn. Acadia Pharmaceuticals has been one of the top performing biopharmas even since its experimental...
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
Business Wire - Tue Jun 17, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014, at 1:30 p.m. Eastern Time in New York City.
Critical Alerts For JPMorgan, Darden Restaurants, BorgWarner, Acadia, and AFLAC Released By InvestorsObserver
PR Newswire - Fri May 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JPM, DRI, BWA, ACAD, and AFL.
10.5% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu May 29, 5:05PM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 10.47% as of today's recent price of $21.25.
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
Business Wire - Tue May 27, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 10:00 a.m. Eastern Time in New York City.
Downtrend Call Working As Acadia Pharmaceuticals Stock Falls 17.3% (ACAD)
Comtex SmarTrend(R) - Thu May 22, 11:05AM CDT
SmarTrend identified a Downtrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on March 25th, 2014 at $23.74. In approximately 2 months, Acadia Pharmaceuticals has returned 17.34% as of today's recent price of $19.62.
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
Business Wire - Tue Apr 01, 8:01AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City.
aTyr Pharma Appoints David M. Weiner, M.D., as Chief Medical Officer
PR Newswire - Fri Mar 28, 7:00AM CDT
aTyr Pharma ("aTyr"
, a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to advance its Physiocrine biology into meaningful therapeutics to treat rare, grave immune disorders. Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
Acadia Pharmaceuticals Has Returned 14.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Tue Mar 11, 9:14AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.28% as of today's recent price of $28.44.
Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
